MX2025011902A - Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk - Google Patents
Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampkInfo
- Publication number
- MX2025011902A MX2025011902A MX2025011902A MX2025011902A MX2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A MX 2025011902 A MX2025011902 A MX 2025011902A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- propionic acid
- tautomers
- acceptable salts
- substituted indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La invención se refiere a derivados de ácido indazol propiónico sustituidos, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos que pueden activar la proteína quinasa activada por adenosina 5'-monofosfato (AMPK). La invención se refiere además a composiciones farmacéuticas que comprenden derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos y al menos un excipiente aceptable desde el punto de vista farmacéutico, y métodos para tratar una afección que comprende administrar derivados de ácido indazol propiónico sustituidos activadores de AMPK, sales aceptables desde el punto de vista farmacéutico, tautómeros, o sales aceptables desde el punto de vista farmacéutico de los tautómeros de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363494598P | 2023-04-06 | 2023-04-06 | |
| PCT/IB2024/053239 WO2024209363A1 (en) | 2023-04-06 | 2024-04-03 | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025011902A true MX2025011902A (es) | 2025-11-03 |
Family
ID=90721385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025011902A MX2025011902A (es) | 2023-04-06 | 2025-10-03 | Compuestos de derivados de acido indazol propionico sustituidos con indazol y usos de estos como activadores de ampk |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240336572A1 (es) |
| EP (1) | EP4688750A1 (es) |
| JP (1) | JP2026515644A (es) |
| KR (1) | KR20250164854A (es) |
| CN (1) | CN121039104A (es) |
| AR (1) | AR132329A1 (es) |
| AU (1) | AU2024249981A1 (es) |
| CO (1) | CO2025013813A2 (es) |
| CR (1) | CR20250419A (es) |
| DO (1) | DOP2025000253A (es) |
| IL (1) | IL323522A (es) |
| MX (1) | MX2025011902A (es) |
| PE (1) | PE20260010A1 (es) |
| TW (1) | TWI899933B (es) |
| WO (1) | WO2024209363A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024209363A1 (en) * | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| WO2026074467A1 (en) * | 2024-10-04 | 2026-04-09 | Pfizer Inc. | Extended release formulations comprising substituted indazole propionic acid derivative compounds and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578850A1 (en) | 1992-07-17 | 1994-01-19 | Biogal Gyogyszergyar | Process for the preparation of carboxylic acids and derivatives of them |
| ES2546815T3 (es) | 2006-12-15 | 2015-09-28 | Bristol-Myers Squibb Company | Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| EP2242757B1 (en) | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| WO2009149837A1 (en) | 2008-06-09 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
| CA2767233A1 (en) | 2009-07-14 | 2011-01-20 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
| EP2993169B1 (en) | 2009-11-17 | 2017-12-20 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| WO2012119046A2 (en) | 2011-03-02 | 2012-09-07 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| EP2694509B1 (en) | 2011-04-05 | 2016-05-18 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| WO2013030138A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| US8889730B2 (en) * | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2014049133A1 (en) | 2012-09-28 | 2014-04-03 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| JP6441830B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| KR20160030001A (ko) | 2014-09-05 | 2016-03-16 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| CA2969164A1 (en) | 2014-12-23 | 2016-06-30 | Genfit | Heterocyclic derivatives as rorgamma modulators |
| WO2016115360A1 (en) | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
| CN108299425B (zh) | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| WO2018229543A2 (en) | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| MX2020006168A (es) | 2017-12-18 | 2020-08-13 | Bristol Myers Squibb Co | Compuestos de 4-azaindol. |
| CN112020496B (zh) | 2018-04-18 | 2023-04-28 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的苯并吡唑类化合物 |
| EP3787612A4 (en) | 2018-05-04 | 2021-11-17 | Remedy Plan, Inc. | CANCER TREATMENTS AGAINST CANCER STEM CELLS |
| EP3813784B1 (en) | 2018-06-07 | 2024-01-10 | The Regents Of The University Of Michigan | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith |
| JP7511564B2 (ja) * | 2018-12-31 | 2024-07-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリア機能不全を治療する方法及び配合物 |
| CN113453753B (zh) | 2019-02-06 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| KR102873783B1 (ko) | 2019-02-25 | 2025-10-21 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
| MX2022014505A (es) * | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| JP2023553835A (ja) | 2020-12-17 | 2023-12-26 | ブロッサムヒル・セラピューティクス・インコーポレイテッド | 大環状化合物およびそれらの使用 |
| WO2022150574A1 (en) | 2021-01-08 | 2022-07-14 | Cornell University | Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase |
| WO2022204150A1 (en) | 2021-03-22 | 2022-09-29 | Blue Oak Pharmaceuticals, Inc. | Compounds and compositions for treating cns disorders |
| TW202304890A (zh) | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| WO2023091707A1 (en) | 2021-11-19 | 2023-05-25 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of jak and methods of use |
| CN119013256A (zh) * | 2022-01-25 | 2024-11-22 | Evvia治疗公司 | Ampk激动剂及其使用方法 |
| EP4504722A4 (en) | 2022-04-04 | 2026-03-18 | Brenig Therapeutics Inc | LRRK2 INHIBITORS |
| WO2024209363A1 (en) * | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
-
2024
- 2024-04-03 WO PCT/IB2024/053239 patent/WO2024209363A1/en not_active Ceased
- 2024-04-03 CN CN202480023808.3A patent/CN121039104A/zh active Pending
- 2024-04-03 EP EP24718603.4A patent/EP4688750A1/en active Pending
- 2024-04-03 PE PE2025002225A patent/PE20260010A1/es unknown
- 2024-04-03 TW TW113112725A patent/TWI899933B/zh active
- 2024-04-03 AU AU2024249981A patent/AU2024249981A1/en active Pending
- 2024-04-03 KR KR1020257036972A patent/KR20250164854A/ko active Pending
- 2024-04-03 CR CR20250419A patent/CR20250419A/es unknown
- 2024-04-03 JP JP2025557975A patent/JP2026515644A/ja active Pending
- 2024-04-04 US US18/626,467 patent/US20240336572A1/en active Pending
- 2024-04-05 AR ARP240100843A patent/AR132329A1/es unknown
-
2025
- 2025-09-22 IL IL323522A patent/IL323522A/en unknown
- 2025-10-03 MX MX2025011902A patent/MX2025011902A/es unknown
- 2025-10-06 CO CONC2025/0013813A patent/CO2025013813A2/es unknown
- 2025-10-06 DO DO2025000253A patent/DOP2025000253A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024249981A1 (en) | 2025-10-16 |
| EP4688750A1 (en) | 2026-02-11 |
| TWI899933B (zh) | 2025-10-01 |
| CN121039104A (zh) | 2025-11-28 |
| CO2025013813A2 (es) | 2025-10-20 |
| US20240336572A1 (en) | 2024-10-10 |
| CR20250419A (es) | 2025-10-07 |
| AR132329A1 (es) | 2025-06-18 |
| TW202448861A (zh) | 2024-12-16 |
| IL323522A (en) | 2025-11-01 |
| KR20250164854A (ko) | 2025-11-25 |
| JP2026515644A (ja) | 2026-05-19 |
| DOP2025000253A (es) | 2025-11-30 |
| PE20260010A1 (es) | 2026-01-06 |
| WO2024209363A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552745A1 (en) | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2022008881A (es) | Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico. | |
| PH12022550783A1 (en) | Antiviral heterocyclic compounds | |
| BRPI0714908B8 (pt) | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| NO20084997L (no) | Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| MX2023009961A (es) | Compuestos heterociclicos antivirales. | |
| MX2024012335A (es) | Compuestos heterociclicos antivirales | |
| CO2025013813A2 (es) | Compuestos derivados de ácido indazolpropiónico sustituidos y usos de los mismos como activadores de ampk | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| MX2025011346A (es) | Compuestos de quinolinona amida y usos de los mismos | |
| MX2025002790A (es) | Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| MX2023014547A (es) | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). | |
| JOP20240258A1 (ar) | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها | |
| AU2021326530A8 (en) | Dosage form compositions comprising an inhibitor of btk and mutants thereof | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| AU2021260669A8 (en) | A formulation for treating ophthalmic conditions |